These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 27909995)

  • 21. Metabolism, Excretion, and Mass Balance of Solithromycin in Humans.
    MacLauchlin C; Schneider SE; Keedy K; Fernandes P; Jamieson BD
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S
    Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea.
    Mancuso AM; Gandhi MA; Slish J
    J Pharm Pract; 2018 Apr; 31(2):195-201. PubMed ID: 28490220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
    Farrell DJ; Sader HS; Castanheira M; Biedenbach DJ; Rhomberg PR; Jones RN
    Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
    Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
    Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections.
    Hawser S; Morrissey I; Lemos B; Keedy K; Fernandes P
    Int J Antimicrob Agents; 2017 Jul; 50(1):17-22. PubMed ID: 28483717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
    Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
    Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.
    Brown SD
    Drug Saf; 2008; 31(7):561-75. PubMed ID: 18558790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae.
    Rodgers W; Frazier AD; Champney WS
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1632-7. PubMed ID: 23318809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.
    Jensen JS; Fernandes P; Unemo M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3151-6. PubMed ID: 24637681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telithromycin: the first of the ketolides.
    Shain CS; Amsden GW
    Ann Pharmacother; 2002 Mar; 36(3):452-64. PubMed ID: 11895060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
    Mathers Dunbar L; Hassman J; Tellier G
    Clin Ther; 2004 Jan; 26(1):48-62. PubMed ID: 14996517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis.
    Llano-Sotelo B; Dunkle J; Klepacki D; Zhang W; Fernandes P; Cate JH; Mankin AS
    Antimicrob Agents Chemother; 2010 Dec; 54(12):4961-70. PubMed ID: 20855725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nature nurtures the design of new semi-synthetic macrolide antibiotics.
    Fernandes P; Martens E; Pereira D
    J Antibiot (Tokyo); 2017 May; 70(5):527-533. PubMed ID: 27899792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
    Tessier PR; Mattoes HM; Dandekar PK; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.